Hexarelin vs Tesamorelin: What's the Difference?

The difference between hexarelin and tesamorelin comes down to what each peptide is and what it is legally allowed to do. Hexarelin is a synthetic ghrelin-mimetic peptide that triggers growth hormone release through the GHS-R1a receptor, and it is not FDA-approved for human use. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that is FDA-approved under the brand name Egrifta to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That single regulatory distinction shapes nearly every practical difference between the two.

What Is Hexarelin?

Hexarelin is a six-amino-acid peptide developed in the 1990s as a growth hormone secretagogue. It mimics ghrelin, sometimes called the hunger hormone, by binding the GHS-R1a receptor in the pituitary and hypothalamus.

What makes hexarelin unusual is that it also binds CD36, a receptor found on heart muscle and other tissues. That non-growth-hormone activity is why much of the hexarelin literature focuses on cardiac effects rather than body composition.

• Peptide class: Synthetic hexapeptide growth hormone secretagogue (ghrelin mimetic)
• Half-life: Short, generally reported at roughly one to two hours
• Main research interests: Growth hormone release, appetite stimulation, cardiac tissue
• FDA status: Not approved for human use in the United States

Hexarelin is typically sold online as a research chemical, which means it is not held to the purity, sterility, or labeling standards that apply to prescription drugs.

What Is Tesamorelin?

Tesamorelin is a 44-amino-acid GHRH analog. It binds GHRH receptors in the pituitary and stimulates the body's own pulsatile growth hormone release, which raises IGF-1 and increases lipolysis in visceral fat.

The FDA approved tesamorelin in 2010, and it remains the only peptide in this comparison with an approved human indication. In clinical trials, daily subcutaneous tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent over 26 weeks in patients with HIV-associated lipodystrophy.

• Approved dose: 1.4 mg or 2 mg once daily by subcutaneous injection
• Half-life: Approximately 26 to 38 minutes
• Main studied effect: Reduction of visceral abdominal fat and an increase in IGF-1
• Availability: Prescription only in the United States

Hexarelin vs Tesamorelin at a Glance

Mechanism of Action: GHRH Analog vs. Ghrelin Mimetic

Tesamorelin works upstream of the pituitary. It copies the body's own GHRH signal, so growth hormone is still released in pulses rather than as a continuous flood.

Hexarelin works through a different doorway. As a ghrelin mimetic, it activates GHS-R1a, which triggers growth hormone release but also influences appetite, gastric emptying, and, through CD36, cardiac tissue.

That difference matters for tolerability. Ghrelin mimetics can lose potency with continuous exposure because the receptor desensitizes, while GHRH analogs such as tesamorelin are typically dosed daily without the same tachyphylaxis.

It also explains why other GHRH-based options get compared so often. In a sermorelin vs tesamorelin discussion, the deciding factors are usually FDA status, half-life, and dosing schedule rather than the receptor itself, since both compounds act on the GHRH receptor.

The same logic applies to cjc-1295 ipamorelin vs tesamorelin: CJC-1295 is a GHRH analog in the same family as tesamorelin, while ipamorelin is a ghrelin mimetic in the same family as hexarelin, so that pairing actually combines both mechanisms described above.

Research Focus: Visceral Fat, Heart Tissue, and GH Stacks

Each peptide has a different center of gravity in the research literature.

• Tesamorelin: Visceral fat reduction in HIV-associated lipodystrophy, IGF-1 elevation, and smaller studies on liver fat and metabolic markers.
• Hexarelin: Growth hormone response, appetite signaling, and cardiac protection in animal models and a small number of human studies.

If body composition is your actual question, aod 9604 vs tesamorelin is the more direct comparison, because AOD-9604 is a growth hormone fragment studied for fat metabolism while tesamorelin works upstream through GHRH.

Much of the online debate around tesamorelin vs hexarelin frames them as interchangeable growth hormone or fat-loss options, but they are not. Only one has an approved indication, a defined dose, and completed large human trials.

Multi-peptide comparisons such as tesamorelin vs sermorelin vs ipamorelin usually blend one GHRH analog with one ghrelin mimetic, which is exactly the split that separates tesamorelin from hexarelin.

Safety, FDA Status, and What to Know Before Use

Tesamorelin is prescription-only and carries label warnings about elevated IGF-1, injection site reactions, joint pain, swelling, and changes in blood sugar. Tesamorelin is not approved for general weight loss in healthy adults, and its approved indication is limited to HIV-associated lipodystrophy.

Hexarelin has no approved human indication. Products sold as hexarelin are unregulated, may be mislabeled, and may contain impurities. Reported effects in studies include appetite increases and short-term growth hormone spikes, but long-term human safety data are limited.

Neither peptide is a treatment for obesity or heart disease, and neither replaces standard medical care. Anyone considering either compound should discuss it with a licensed healthcare professional first, especially people with diabetes, a cancer history, or pituitary disease.

The bottom line: tesamorelin is the evidence-backed, FDA-approved option for one narrow condition, and hexarelin is an unapproved research peptide with a very different mechanism and far less human data.